Search for content, post, videos

BioInvent announces agreement with MSD

Martin Welschof

BioInvent International has announced a clinical trial collaboration and supply agreement with MSD International Business for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA.

Under the terms of the supply agreement, MSD will provide its anti-PD-1 therapy KEYTRUDA to be used in combination with BI-1910. The Phase 1/2a trial will be conducted in the US and Europe and has an innovative, adaptive design to allow for ideal dose escalation.


BI-1910 is BioInvent’s second tumor necrosis factor receptor 2 (TNFR2) program to enter clinical development, after BI-1808 currently in Phase 2a. BI-1910 displays a differentiated, agonist approach to cancer treatment compared to BI-1808, BioInvent’s first-in-class anti-TNFR2 antibody. Both monoclonal antibodies were chosen as potential best-in-class, from a large family of binders generated through BioInvent’s proprietary F.I.R.S.T technology platform. The single agent arm of the Phase 1/2a BI-1910 study was initiated in December 2023 and first data is expected by YE 2024.

“We are delighted to enter into another clinical trial collaboration and supply agreement with MSD to investigate the unique features of BI-1910 in combination with KEYTRUDA. This trial will build on our deep understanding of the TNFR2 biology as we move two differentiated monoclonal antibodies through clinical development. This is our fifth product in ongoing clinical trials, demonstrating the capacity of BioInvent’s technology to identify novel, first-in-class therapeutic cancer targets,” said Martin Welschof, CEO of BioInvent.

Photo of Martin Welschof: Nille Leander